The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial
Completed
GlaxoSmithKline
Phase 3
2006-07-01
This is a randomized, double-blind, double-dummy, parallel group trial employing 15 cells of
a 4x4 factorial design (no placebo)to compare the hypertensive effects in patients with Stage
1 and Stage 2 hypertension of carvedilol (20, 40 or 80 mg daily) alone, lisinopril (10, 20 or
40 mg daily) alone, and all combinations of the doses.
A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.
Completed
GlaxoSmithKline
Phase 1
2007-09-01
This study will be a randomized study investigating the bioequivalence of COREG CR to its
components, COREG and Lisinopril (ZESTRIL). PK samples will be obtained throughout the study
to investigate the PK of COREG CR FDC to COREG and Lisinopril
Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors
Terminated
Comprehensive Cancer Center of Wake Forest University
Phase 2
2011-02-01
RATIONALE: Benazepril hydrochloride, lisinopril, ramipril, and losartan potassium may help
lower blood pressure.
PURPOSE: This phase II trial is studying how well benazepril hydrochloride, lisinopril,
ramipril, or losartan potassium works in treating hypertension in patients with solid tumors.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
